Denise Carter
Founder bei QUOIN PHARMACEUTICALS, LTD.
Vermögen: 8 889 $ am 31.03.2024
Profil
Denise Carter is the founder of Quoin Pharmaceuticals Ltd.
She founded the company in 2018 and currently holds the position of Chief Operating Officer & Director.
Ms. Carter is also the founder of Quoin Pharmaceuticals, Inc. Ms. Carter's former job positions include Director-Business Development at Fuisz Technologies Ltd.
from 1996 to 1999, Senior Director-Business Development at Eurand, Inc. from 2000 to 2001, Director-Business Development at Cardinal Health, Inc. from 1999 to 2000, and Vice President-Business Development at West Pharmaceutical Services, Inc. from 2001 to 2003.
She also served as EVP-Business Development & Corporate Affairs at Innocoll, Inc. from 2003 to 2015.
Ms. Carter's education history includes an undergraduate degree from The College of William & Mary and an MBA from The Wharton School of the University of Pennsylvania.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 13.03.2024 | 9 357 ( 0,25% ) | 8 889 $ | 31.03.2024 |
Aktive Positionen von Denise Carter
| Unternehmen | Position | Beginn |
|---|---|---|
| QUOIN PHARMACEUTICALS, LTD. | Founder | 05.03.2018 |
Ehemalige bekannte Positionen von Denise Carter
| Unternehmen | Position | Ende |
|---|---|---|
Innocoll, Inc.
 Innocoll, Inc. Pharmaceuticals: MajorHealth Technology Innocoll, Inc. developed and manufactured pharmaceutical products and medical devices. The company was headquartered in Ashburn, VA. | Investor Relations Contact | 01.10.2015 |
| WEST PHARMACEUTICAL SERVICES, INC. | Corporate Officer/Principal | 01.01.2003 |
Eurand, Inc.
 Eurand, Inc. Pharmaceuticals: MajorHealth Technology Eurand, Inc. develops pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies. The company has had three products approved by the FDA since 2000. The company's most advanced development product, a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and other diseases, is currently undergoing Phase III clinical trials in the United States. It's technology platforms include: bioavailability enhancement of poorly soluble drugs, customized release, taste masking/fast dissolving formulations and drug conjugation. The company was founded in 1969 and is headquartered in Vandalia, OH. | Corporate Officer/Principal | 01.01.2001 |
| CARDINAL HEALTH, INC. | Corporate Officer/Principal | 01.01.2000 |
Fuisz Technologies Ltd.
 Fuisz Technologies Ltd. Pharmaceuticals: MajorHealth Technology Part of Bausch Health Cos., Inc., Fuisz Technologies Ltd. is a private company that develops and commercializes rapid dissolving tablets for over-the-counter and prescription pharmaceuticals. The company is based in Chantilly, VA. Fuisz Technologies was acquired by Biovail Corp. on November 12, 1999 for $145.48 million. | Corporate Officer/Principal | 01.01.1999 |
Ausbildung von Denise Carter
| The College of William & Mary | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| CARDINAL HEALTH, INC. | Distribution Services |
| WEST PHARMACEUTICAL SERVICES, INC. | Health Technology |
| QUOIN PHARMACEUTICALS, LTD. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Fuisz Technologies Ltd.
Fuisz Technologies Ltd. Pharmaceuticals: MajorHealth Technology Part of Bausch Health Cos., Inc., Fuisz Technologies Ltd. is a private company that develops and commercializes rapid dissolving tablets for over-the-counter and prescription pharmaceuticals. The company is based in Chantilly, VA. Fuisz Technologies was acquired by Biovail Corp. on November 12, 1999 for $145.48 million. | Health Technology |
Eurand, Inc.
Eurand, Inc. Pharmaceuticals: MajorHealth Technology Eurand, Inc. develops pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies. The company has had three products approved by the FDA since 2000. The company's most advanced development product, a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and other diseases, is currently undergoing Phase III clinical trials in the United States. It's technology platforms include: bioavailability enhancement of poorly soluble drugs, customized release, taste masking/fast dissolving formulations and drug conjugation. The company was founded in 1969 and is headquartered in Vandalia, OH. | Health Technology |
Innocoll, Inc.
Innocoll, Inc. Pharmaceuticals: MajorHealth Technology Innocoll, Inc. developed and manufactured pharmaceutical products and medical devices. The company was headquartered in Ashburn, VA. | Health Technology |
Quoin Pharmaceuticals, Inc.
 Quoin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quoin Pharmaceuticals, Inc. manufactures pharmaceutical products. The company is headquartered in Las Vegas, NV. | Health Technology |
